Vismodegib in basal cell carcinoma

Drugs of Today

Volumn 48, Issue 7, 2012, Pages 459-467

  Amaria, R N ^a   Bowles, D W ^a   Lewis, K D ^a   Jimeno, A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Basal cell carcinoma; Basal cell nevus syndrome; Targeted therapy; Vismodegib

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MACROLIDE; OXALIPLATIN; PLACEBO; VISMODEGIB;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CLINICAL PHARMACOLOGY; CLINICAL STUDY; COLON CANCER; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DYSGEUSIA; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEDGEHOG; HUMAN; HYPONATREMIA; METASTASIS; MUSCLE SPASM; NAUSEA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SIDE EFFECT; TASTE AVERSION; THORAX PAIN; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; EVIDENCE-BASED MEDICINE; HUMANS; PYRIDINES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84864793869     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.7.1808490     Document Type: Article

References (35)

1. Chinem, V.P., Miot, H.A. Epidemiology of basal cell carcinoma. An Bras Dermatol 2011, 86(2): 292-305.
2. Rubin, A.I., Chen, E.H., Ratner, D. Basal-cell carcinoma. N Engl J Med 2005, 353(21): 2262-9. (Pubitemid 41697289)
3. Christenson, L.J., Borrowman, T.A., Vachon, C.M., Tollefson, M.M., Otley, C.C., Weaver, A.L., Roenigk, R.K. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005, 294(6): 681-90. (Pubitemid 41159287)
4. Leger, M., Quintana, A., Tzu, J., Yee, H., Kamino, H., Sanchez, M. Nevoid basal cell carcinoma syndrome. Dermatol Online J 2011, 17(10): 23.
5. Kimonis, V.E., Goldstein, A.M., Pastakia, B. et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997, 69(3): 299-308. (Pubitemid 27154674)
6. Tang, J.Y. Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma. Semin Cutan Med Surg 2011, 30(4, Suppl.): S6-9.
7. Taipale, J., Beachy, P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001, 411(6835): 349-54. (Pubitemid 32467044)
8. Nusslein-Volhard, C., Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 1980, 287(5785): 795-801. (Pubitemid 11214475)
9. Ingham, P.W., McMahon, A.P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001, 15(23): 3059-87. (Pubitemid 33115673)
10. Hahn, H., Wicking, C., Zaphiropoulous, P.G. et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85(6): 841-51. (Pubitemid 26192135)
11. Johnson, R.L., Rothman, A.L., Xie, J. et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996, 272(5268): 1668-71. (Pubitemid 26200029)
12. Binns, W., James, L.F., Shupe, J.L., Thacker, E.J. Cyclopiantype malformation in lambs. Arch Environ Health 1962, 5: 106-8.
13. Binns, W., Shupe, J.L., Keeler, R.F., James, L.F. Chronologic evaluation of teratogenicity in sheep fed Veratrum californicum. J Am Vet Med Assoc 1965, 147(8): 839-42.
14. Cooper, M.K., Porter, J.A., Young, K.E., Beachy, P.A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 1998, 280(5369): 1603-7. (Pubitemid 28277705)
15. Chen, J.K., Taipale, J., Cooper, M.K., Beachy, P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002, 16(21): 2743-8. (Pubitemid 35253140)
16. Taipale, J., Chen, J.K., Cooper, M.K. et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000, 406(6799): 1005-9.
17. Vismodegib [package insert] . Genentech, January 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203388lbl.pdf. Accessed March 22, 2012.
18. Wong, H., Chen, J.Z., Chou, B. et al. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica 2009, 39(11): 850-61.
19. Giannetti, A.M., Wong, H., Dijkgraaf, G.J. et al. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem 2011, 54(8): 2592-601.
20. Wong, H., Alicke, B., West, K.A. et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res 2011, 17(14): 4682-92.
21. LoRusso, P.M., Rudin, C.M., Reddy, J.C. et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011, 17(8): 2502-11.
22. Von Hoff, D.D., LoRusso, P.M., Rudin, C.M. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361(12): 1164-72.
23. Ding, X., Chou, B., Graham, R.A. et al. Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878(9-10): 785-90.
24. Graham, R.A., Lum, B.L., Cheeti, S. et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011, 17(8): 2512-20.
25. Duche, J.C., Urien, S., Simon, N., Malaurie, E., Monnet, I., Barre, J. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem 2000, 33(3): 197-202. (Pubitemid 30489064)
26. Delbaldo, C., Chatelut, E., Re, M. et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006, 12(20, Pt. 1): 6073-8. (Pubitemid 44703771)
27. Lu, J.F., Eppler, S.M., Wolf, J., Hamilton, M., Rakhit, A., Bruno, R., Lum, B.L. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006, 80(2): 136-45. (Pubitemid 44160689)
28. Lorusso, P.M., Jimeno, A., Dy, G. et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011, 17(17): 5774-82.
29. Sekulic, A., Migden, M.R., Oro, A.E. et al. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC). Eur Assoc Dermato-Oncol (June 21, Nantes, France) 2011, Abst C014.
30. Sekulic, A., Migden, M.R., Oro, A.E. et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012, 366(23): 2171-9.
31. Tang, J.Y., Mackay-Wiggan, J.M., Aszterbaum, M. et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012, 366(23): 2180-8.
32. Singh, B.N., Fu, J., Srivastava, R.K., Shankar, S. Hedgehog signaling antagonist GDC-0449 (vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 2011, 6(11): e27306.
33. Ng, J.M., Curran, T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011, 11(7): 493-501.
34. Yauch, R.L., Dijkgraaf, G.J., Alicke, B. et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326(5952): 572-4.
35. Buonamici, S., Williams, J., Morrissey, M. et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010, 2(51): 51ra70.